Prabhudas Lilladher has issued a 'Buy' rating with a target of ₹1,650 for Rainbow Children’s Medicare. The brokerage remains optimistic about future growth as the company completes a major expansion phase, despite recent margin compression seen in the Q2 FY27 results.
Prabhudas Lilladher has initiated a 'Buy' rating on Rainbow Children’s Medicare, setting a target price of ₹1,650 per share. This development comes as the hospital chain navigates the final stages of an aggressive two-year expansion cycle that has increased its total bed capacity by 50%. The stock is currently trading in the ₹1,200–₹1,250 range, reflecting a period where investors are weighing the company's rapid scaling against short-term profitability challenges.
The brokerage's optimistic outlook is built on the expectation that earnings will accelerate as the new hospital facilities move toward full utilization. In its recent Q2 FY27 results declared on November 2, 2026, the company reported a year-over-year revenue growth of 23%–25%, reaching approximately ₹5,480–5,500 million. However, net profit came in at ₹820 million, and EBITDA margins compressed to 31.0%, down from 33.5% in the same period last year. This margin pressure is primarily attributed to the higher operational, staff, and professional costs associated with commissioning new beds.
The Path to Margin Recovery
Analysts at the brokerage firm project a 19% EBITDA compound annual growth rate (CAGR) between fiscal years 2026 and 2029. The core thesis rests on the belief that the intensive capital spending phase is largely complete. As these new units reach optimal occupancy levels, the fixed costs of running these hospitals are expected to be spread across a higher base of patient revenue, which would logically support margin expansion.
Despite the positive long-term view, investors are monitoring specific risks inherent in this phase of the company's growth. The hospital chain faces the critical task of achieving its target occupancy levels of 55%–60% across the newly opened facilities. Any delay in ramping up patient volumes could keep operational costs elevated for longer than anticipated. Furthermore, the specialized pediatric healthcare sector in India remains highly competitive, with established players and new entrants vying for market share, which can impact pricing power.
For investors, the immediate monitorables will be the speed at which the newly commissioned beds achieve profitable occupancy levels. Future updates from management regarding clinical hiring, patient footfall in the new units, and improvements in EBITDA margins will be essential to track. As the company transitions from this capital-intensive expansion phase to a period focused on operational efficiency, the sustainability of its free cash flow and return ratios will remain a key area of focus for the market.